Association between clinical dementia rating and clinical outcomes in Alzheimer's disease
Abstract INTRODUCTION We examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI‐Q]), and cognitive impairment in Alzheimer's disease (AD). METHODS We used d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.12522 |
| _version_ | 1797242540138692608 |
|---|---|
| author | Krista L. Lanctôt Mercè Boada Pierre N. Tariot Firas Dabbous Julie Hahn‐Pedersen Sariya Udayachalerm Lars Lau Raket Cynthia Saiontz‐Martinez Wojciech Michalak Wendy Weidner Jeffrey Cummings |
| author_facet | Krista L. Lanctôt Mercè Boada Pierre N. Tariot Firas Dabbous Julie Hahn‐Pedersen Sariya Udayachalerm Lars Lau Raket Cynthia Saiontz‐Martinez Wojciech Michalak Wendy Weidner Jeffrey Cummings |
| author_sort | Krista L. Lanctôt |
| collection | DOAJ |
| description | Abstract INTRODUCTION We examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI‐Q]), and cognitive impairment in Alzheimer's disease (AD). METHODS We used data from the National Alzheimer's Coordinating Center Uniform Data Set and defined cognitively unimpaired and AD stages using CDR‐global. RESULTS Functional and neuropsychiatric symptoms occur as early as the mild cognitive impairment (MCI) phase. The adjusted lest square mean FAS (95% confidence interval [CI]) was lowest in cognitively unimpaired (3.88 [3.66, 4.11] to 5.01 [4.76, 5.26]) and higher with more advanced AD (MCI: 8.17 [6.92, 9.43] to 20.87 [19.53, 22.20]; mild: 18.54 [17.57, 19.50] to 28.13 [27.14, 29.12]; moderate: 26.01 [25.31, 26.70] to 29.42 [28.73, 30.10]). FAS and NPI‐Q scores increased steeply with MCI (NPI‐Q: 5.55 [4.89, 6.20] to 7.11 [6.43, 7.78]) and mild AD dementia (NPI‐Q: 6.66 [5.72, 7.60] to 8.32 [7.32, 9.33]). DISCUSSION CDR‐global staged AD by capturing differences in relevant outcomes along AD progression. Highlights There were strong associations among CDR and the various outcomes relevant to healthcare providers, patients, and their care givers, such as activities of daily living. Overall, activities of daily living, neuropsychiatric symptoms, and cognitive function outcomes deteriorated over time and can be observed in early stages of AD (MCI or mild dementia). Our findings directly inform the current understanding of AD progression and can aid in care planning and benefit assessments of early AD interventions to delay the progression of AD to more advanced stages. |
| first_indexed | 2024-04-24T18:40:50Z |
| format | Article |
| id | doaj.art-439da02a121f44439d983700c601118d |
| institution | Directory Open Access Journal |
| issn | 2352-8729 |
| language | English |
| last_indexed | 2024-04-24T18:40:50Z |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj.art-439da02a121f44439d983700c601118d2024-03-27T13:14:40ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292024-01-01161n/an/a10.1002/dad2.12522Association between clinical dementia rating and clinical outcomes in Alzheimer's diseaseKrista L. Lanctôt0Mercè Boada1Pierre N. Tariot2Firas Dabbous3Julie Hahn‐Pedersen4Sariya Udayachalerm5Lars Lau Raket6Cynthia Saiontz‐Martinez7Wojciech Michalak8Wendy Weidner9Jeffrey Cummings10Hurvitz Brain Sciences ProgramSunnybrook Research InstituteToronto Ontario CanadaAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaBarcelona SpainBanner Alzheimer's Institute Phoenix Arizona USAData AnalyticsEvideraBethesda Maryland USANovo Nordisk A/SSøborg DenmarkData AnalyticsEvideraBethesda Maryland USANovo Nordisk A/SSøborg DenmarkData AnalyticsEvideraBethesda Maryland USANovo Nordisk A/SSøborg DenmarkAlzheimer's Disease International London UKDepartment of Brain Health, Chambers‐Grundy Center for Transformative NeuroscienceUNLVLas Vegas Nevada USAAbstract INTRODUCTION We examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI‐Q]), and cognitive impairment in Alzheimer's disease (AD). METHODS We used data from the National Alzheimer's Coordinating Center Uniform Data Set and defined cognitively unimpaired and AD stages using CDR‐global. RESULTS Functional and neuropsychiatric symptoms occur as early as the mild cognitive impairment (MCI) phase. The adjusted lest square mean FAS (95% confidence interval [CI]) was lowest in cognitively unimpaired (3.88 [3.66, 4.11] to 5.01 [4.76, 5.26]) and higher with more advanced AD (MCI: 8.17 [6.92, 9.43] to 20.87 [19.53, 22.20]; mild: 18.54 [17.57, 19.50] to 28.13 [27.14, 29.12]; moderate: 26.01 [25.31, 26.70] to 29.42 [28.73, 30.10]). FAS and NPI‐Q scores increased steeply with MCI (NPI‐Q: 5.55 [4.89, 6.20] to 7.11 [6.43, 7.78]) and mild AD dementia (NPI‐Q: 6.66 [5.72, 7.60] to 8.32 [7.32, 9.33]). DISCUSSION CDR‐global staged AD by capturing differences in relevant outcomes along AD progression. Highlights There were strong associations among CDR and the various outcomes relevant to healthcare providers, patients, and their care givers, such as activities of daily living. Overall, activities of daily living, neuropsychiatric symptoms, and cognitive function outcomes deteriorated over time and can be observed in early stages of AD (MCI or mild dementia). Our findings directly inform the current understanding of AD progression and can aid in care planning and benefit assessments of early AD interventions to delay the progression of AD to more advanced stages.https://doi.org/10.1002/dad2.12522activities of daily livingAlzheimer's diseaseclinical dementia rating scalecognitive impairmentdementia |
| spellingShingle | Krista L. Lanctôt Mercè Boada Pierre N. Tariot Firas Dabbous Julie Hahn‐Pedersen Sariya Udayachalerm Lars Lau Raket Cynthia Saiontz‐Martinez Wojciech Michalak Wendy Weidner Jeffrey Cummings Association between clinical dementia rating and clinical outcomes in Alzheimer's disease Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring activities of daily living Alzheimer's disease clinical dementia rating scale cognitive impairment dementia |
| title | Association between clinical dementia rating and clinical outcomes in Alzheimer's disease |
| title_full | Association between clinical dementia rating and clinical outcomes in Alzheimer's disease |
| title_fullStr | Association between clinical dementia rating and clinical outcomes in Alzheimer's disease |
| title_full_unstemmed | Association between clinical dementia rating and clinical outcomes in Alzheimer's disease |
| title_short | Association between clinical dementia rating and clinical outcomes in Alzheimer's disease |
| title_sort | association between clinical dementia rating and clinical outcomes in alzheimer s disease |
| topic | activities of daily living Alzheimer's disease clinical dementia rating scale cognitive impairment dementia |
| url | https://doi.org/10.1002/dad2.12522 |
| work_keys_str_mv | AT kristallanctot associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT merceboada associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT pierrentariot associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT firasdabbous associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT juliehahnpedersen associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT sariyaudayachalerm associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT larslauraket associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT cynthiasaiontzmartinez associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT wojciechmichalak associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT wendyweidner associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease AT jeffreycummings associationbetweenclinicaldementiaratingandclinicaloutcomesinalzheimersdisease |